Predicting response to platinum chemotherapy in metastatic castration resistant prostate cancer (mCRPC) using a genomic signature for “BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC who have progressed on docetaxel.

Authors

S. M. Seng

Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY

S. M. Seng , M. D. Galsky , C. Tsao , J. Li , P. G. Febbo , W. K. Oh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In